Similar articles

• [Advanced hepatocellular carcinoma: value of systemic chemotherapy combining adriamycin, amiodarone and 5-fluorouracil].

  Bedenne L, Chauffert B, Lorcerie B, Faivre J, Hillon P, Klepping C, Martin F. Bedenne L, et al. Gastroenterol Clin Biol. 1989 Oct;13(10):845-6. Gastroenterol Clin Biol. 1989. PMID: 2556316 French. No abstract available.
• Adriamycin and 5-fluorouracil in the treatment of advanced hepatoma: a Southwest Oncology Group study.

  Baker LH, Saiki JH, Jones SE, Hewlett JS, Brownlee RW, Stephens RL, Vaitkevicius VK. Baker LH, et al. Cancer Treat Rep. 1977 Nov;61(8):1595-7. Cancer Treat Rep. 1977. PMID: 200359 No abstract available.
• Treatment of primary liver cancer: response to regional chemotherapy.

  Wellwood JM, Cady B, Oberfield RA. Wellwood JM, et al. Clin Oncol. 1979 Mar;5(1):25-31. Clin Oncol. 1979. PMID: 217565 No abstract available.
• Receptor-mediated protection of normal hepatocytes during chemotherapy for hepatocellular carcinoma.

  Keegan-Rogers V, Wu CH, Wu GY. Keegan-Rogers V, et al. Targeted Diagn Ther. 1991;4:105-25. Targeted Diagn Ther. 1991. PMID: 1665717 Review. No abstract available.
• Medical treatment of hepatocellular carcinoma.

  Nerenstone S, Friedman M. Nerenstone S, et al. Gastroenterol Clin North Am. 1987 Dec;16(4):603-12. Gastroenterol Clin North Am. 1987. PMID: 2831153 Review.